Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Sep 16 - Sep 21
With the rising popularity of GLP-1 receptor agonists for weight loss, two medications have emerged as front-runners: tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy)
Both options require multiple sessions depending on treatment goals, but providers should consider cost transparency , session planning , and patient expectations when recommending one over the other
A phase 3 trial is currently evaluating retatrutide directly against tirzepatide in adults with obesity
By mastering these simple but crucial techniques, you're not just protecting a vial of peptideyou're safeguarding the future of your research
But the results tend to be more durable because the underlying metabolic drivers have changed, not just suppressed
